PHARMATRUST
ActiveSummary
PHARMATRUST has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €401,657 and a net result of €138,857. Equity is growing by about 28% per year across the filed financial years. Its solvency ranks better than 69% of 12,404 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 31 days late
2025
31-12
Financial
Highest result from 2018 to 2025net €138,857 ▲154%
Operating result €190,900, net result €138,857, both a record.
28-08
NBB filing
Annual accounts filed
financial year 2024 · full format · 28 days late
2024
30-08
NBB filing
Annual accounts filed
financial year 2023 · full format · 30 days late
2023
31-12
Financial
Equity above €200,000equity €208,111 ▲6.6%
5 profitable years in a row build equity to €208,111.
13-07
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
31-12
Financial
Equity above €150,000equity €195,242 ▲37.7%
4 profitable years in a row build equity to €195,242.
29-07
NBB filing
Annual accounts filed
financial year 2021 · full format
2021
31-12
Financial
Equity above €100,000equity €141,828 ▲70.1%
3 profitable years in a row build equity to €141,828.
30-09
NBB filing
Annual accounts filed
financial year 2020 · micro format · 61 days late
2020
30-11
NBB filing
Annual accounts filed
financial year 2019 · micro format · 122 days late
2019
31-12
Financial
Back to profitnet €41,058
Net result €41,058 after one loss-making year.
31-08
NBB filing
Annual accounts filed
financial year 2018 · micro format · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.